Asset Management One Co. Ltd. Has $22.28 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Asset Management One Co. Ltd. trimmed its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 290,402 shares of the medical research company's stock after selling 32,822 shares during the period. Asset Management One Co. Ltd.'s holdings in Edwards Lifesciences were worth $22,277,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of EW. Moneta Group Investment Advisors LLC boosted its holdings in Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock worth $1,148,938,000 after buying an additional 15,384,593 shares during the last quarter. Norges Bank acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its holdings in shares of Edwards Lifesciences by 440.0% during the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company's stock worth $243,173,000 after purchasing an additional 2,860,000 shares during the last quarter. AustralianSuper Pty Ltd acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Edwards Lifesciences by 655.9% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company's stock worth $173,502,000 after purchasing an additional 2,017,801 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Mizuho upped their price objective on Edwards Lifesciences from $85.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, February 7th. Evercore ISI boosted their target price on Edwards Lifesciences from $86.00 to $92.00 and gave the company an "in-line" rating in a research report on Thursday. Morgan Stanley boosted their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a research report on Thursday, March 21st. Oppenheimer boosted their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a research report on Monday, March 18th. Finally, StockNews.com lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $90.67.

Insider Activity at Edwards Lifesciences

In related news, Director Michael A. Mussallem sold 29,350 shares of the firm's stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total value of $2,712,527.00. Following the transaction, the director now owns 4,486 shares in the company, valued at $414,596.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 10,000 shares of the firm's stock in a transaction on Friday, January 12th. The stock was sold at an average price of $75.67, for a total value of $756,700.00. Following the sale, the vice president now directly owns 39,503 shares in the company, valued at $2,989,192.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the firm's stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the sale, the director now owns 4,486 shares in the company, valued at $414,596.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 189,604 shares of company stock worth $16,593,546. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $1.50 during mid-day trading on Friday, reaching $92.70. The company had a trading volume of 2,561,359 shares, compared to its average volume of 3,581,903. The stock's 50-day simple moving average is $88.67 and its 200-day simple moving average is $76.96. The company has a market capitalization of $55.80 billion, a P/E ratio of 40.30, a P/E/G ratio of 4.52 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts' consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. During the same period in the prior year, the company earned $0.64 EPS. The firm's revenue was up 13.3% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.